Secretin for the Treatment of Autism

PHASE3CompletedINTERVENTIONAL
Enrollment

85

Participants

Timeline

Start Date

June 30, 1999

Study Completion Date

May 31, 2000

Conditions
Autism
Interventions
DRUG

secretin, synthetic porcine

DRUG

secretin, biologically derived porcine

Trial Locations (2)

80218

Children's Hospital, Denver

98195-1525

Center on Human Development and Disability, Seattle

All Listed Sponsors
collaborator

National Institute on Deafness and Other Communication Disorders (NIDCD)

NIH

lead

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

NCT00065962 - Secretin for the Treatment of Autism | Biotech Hunter | Biotech Hunter